GENDRON PAUL ANDREW
Known title: DirectorCIK: 0001769450
GENDRON PAUL ANDREW's purchase track record
GENDRON PAUL ANDREW has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | INFU | $44K | +48.5% | pending | — |
| 5/20/2024 | INFU | $33K | -1.8% | +38.5% | +11.0% |
| 2/11/2022 | INFU | $107K | -20.2% | -24.4% | -3.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INFU | ▲ Buy | Open Market | 5,000 | $44K | 5/8/2026 | View on chart |
| INFU | ▲ Buy | Open Market | 5,000 | $33K | 5/20/2024 | View on chart |
| INFU | ▲ Buy | Open Market | 10,000 | $107K | 2/11/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 25,000 | $118K | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.